1. Generics Bulletin
  2. >>Products

Lilly’s Humalog Authorized Generic Will Not Quash Price Pressure

 
• By Dave Wallace

Eli Lilly has announced plans to introduce a generic version of its Humalog insulin lispro in the US at a 50% discount to the brand’s list price. However, political pressure is continuing to mount over the lack of availability of cheaper alternatives.

ClampCoins
Political Pressure On Insulin Pricing Continues Despite Lilly’s Launch • Source: Shutterstock

Eli Lilly will launch an authorized generic version of its Humalog (insulin lispro) 100U/ml in the US at a 50% discount to the brand’s list price, the firm has announced.

Called Insulin Lispro, the generic will be available in both vial and pen presentations, with a list price of US$137.35...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Regulatory Recap: EU Pharma Package Progresses Forward With Extended Data Protection

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By Dean Rudge

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.